From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries
Introduction Almost 8,000 rare diseases exist worldwide, affecting approximately 350 million people. Nevertheless, only 5% receive a specific authorized or licensed treatment. The need for effective and rapidly available therapies is still unmet for many patients. Objective The objective is to defin...
Main Authors: | Paola Minghetti, Elena P. Lanati, Josie Godfrey, Oriol Solà-Morales, Olivier Wong, Sonia Selletti |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-01-01
|
Series: | Medicine Access @ Point of Care |
Online Access: | https://doi.org/10.5301/maapoc.0000016 |
Similar Items
-
Off-Label Drug Use in Oncology
by: E. V. Karabina, et al.
Published: (2022-07-01) -
On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients
by: Ciska Verbaanderd, et al.
Published: (2020-01-01) -
Oncology Drug Repurposing for Sepsis Treatment
by: Izabela Rumienczyk, et al.
Published: (2022-04-01) -
The Role of Dopamine in Repurposing Drugs for Oncology
by: Catarina Moura, et al.
Published: (2023-07-01) -
Repurposing Drugs in Small Animal Oncology
by: Antonio Giuliano, et al.
Published: (2022-12-01)